Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.76 |
| ▸ | NPC1 | O15118 | 10/20 | 0.74 |
| ▸ | RAB9A | P51151 | 9/20 | 0.74 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.74 |
| ▸ | MITF | O75030 | 1/20 | 0.74 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.74 |
| ▸ | PKM | P14618 | 2/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.69 |
| ▸ | MEN1 | O00255 | 7/20 | 0.69 |
| ▸ | HPGD | P15428 | 1/20 | 0.68 |
| ▸ | GPR174 | Q9BXC1 | 1/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.68 |
| ▸ | POLB | P06746 | 2/20 | 0.67 |
| ▸ | LMNA | P02545 | 2/20 | 0.67 |
| ▸ | GAA | P10253 | 1/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.67 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.64 |
| ▸ | GBA1 | P04062 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10576308 | 0.93 | MAPT (0.86) | MAPTNPC1RAB9ASMN1; SMN2MITF | |
| Phenacetin SCHEMBL27622268 | 0.88 | KMT2A (0.87) | MAPTNPC1RAB9ASMN1; SMN2MITF | |
| SCHEMBL5174837 | 0.87 | MEN1 (0.73) | MAPTNPC1RAB9ASMN1; SMN2MITF | |
| SCHEMBL4111978 | 0.87 | NPC1 (0.75) | MAPTNPC1RAB9ASMN1; SMN2MITF | |
| SCHEMBL4104949 | 0.87 | PPARA (0.68) | MAPTNPC1RAB9ASMN1; SMN2MITF | |
| SCHEMBL14470413 | 0.86 | POLB (0.74) | MAPTNPC1RAB9ASMN1; SMN2MITF | |
| SCHEMBL4112735 | 0.85 | NPC1 (0.68) | MAPTNPC1RAB9ASMN1; SMN2MITF | |
| SCHEMBL4105709 | 0.85 | MAPT (0.73) | MAPTNPC1RAB9ASMN1; SMN2MITF | |
| SCHEMBL4113061 | 0.85 | MAPT (0.73) | MAPTNPC1RAB9ASMN1; SMN2MITF | |
| SCHEMBL4117849 | 0.85 | MAPT (0.73) | MAPTNPC1RAB9ASMN1; SMN2MITF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090239841-A1 | Diaryl Ureas as CB1 Antagonists | NEUROGEN CORPORATION | 2009-09-24 | — | — | US | claimed |
| EP-1804785-A2 | DIARYL UREAS AS CB1 ANTAGONISTS | NEUROGEN CORPORATION (US) | 2007-07-11 | — | — | EP | claimed |
| WO-2006049941-A2 | DIARYL UREAS AS CB1 ANTAGONISTS | NEUROGEN CORPORATION (US) | 2006-05-11 | — | — | WO | claimed |
| US-20120214808-A1 | Aryl Urea Derivatives for Treating Obesity | PROSIDION LIMITED (GB) | 2012-08-23 | — | — | US | disclosed |
| US-20120214808-A1 | Aryl Urea Derivatives for Treating Obesity | PROSIDION LIMITED (GB) | 2012-08-23 | — | — | US | disclosed |
| US-20090239841-A1 | Diaryl Ureas as CB1 Antagonists | NEUROGEN CORPORATION | 2009-09-24 | — | — | US | disclosed |
| US-20090239841-A1 | Diaryl Ureas as CB1 Antagonists | NEUROGEN CORPORATION | 2009-09-24 | — | — | US | disclosed |
| US-20090239841-A1 | Diaryl Ureas as CB1 Antagonists | NEUROGEN CORPORATION | 2009-09-24 | — | — | US | disclosed |
| US-20080261952-A1 | Aryl Urea Derivatives for Treating Obesity | PROSIDION LTD. (GB) | 2008-10-23 | — | — | US | disclosed |
| US-20080261952-A1 | Aryl Urea Derivatives for Treating Obesity | PROSIDION LTD. (GB) | 2008-10-23 | — | — | US | disclosed |
| US-20080261952-A1 | Aryl Urea Derivatives for Treating Obesity | PROSIDION LTD. (GB) | 2008-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239841-A1 | Diaryl Ureas as CB1 Antagonists | CNR1, CNR2, OPRL1 | MAPT 1654/4885NPC1 927/4885RAB9A 815/4885 |
| US-20080261952-A1 | Aryl Urea Derivatives for Treating Obesity | CNR1, GPR119, UTS2R | MAPT 4151/4885NPC1 148/4885RAB9A 3359/4885 |
| US-20120214808-A1 | Aryl Urea Derivatives for Treating Obesity | CNR1, GPR119, UTS2R | MAPT 4151/4885NPC1 148/4885RAB9A 3359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.